Neocis

Overview

Neocis is a Miami-based medical technology company specializing in robotic-assisted surgery for the dental industry. Founded by Alon Mozes and Juan Salcedo in 2009, the company is renowned for its Yomi system, the first and only FDA-cleared robotic device for dental surgery. As of 2024, Neocis has raised approximately $237 million in funding and is a leader in transforming dental implant procedures through advanced robotics.

Recent Developments

January 2024: Neocis announced it raised $20 million in additional funding from investors including Mirae Asset Financial Group and NVIDIA, emphasizing growth and further research and development.
Throughout 2023: Despite challenging economic conditions, Neocis managed to secure $20 million in financing, showcasing resilience and ongoing growth.
2023: Neocis was recognized as one of South Florida's 50 fastest growing companies by the South Florida Business Journal.
2022: The company completed a financing round worth $40 million, led by Intuitive Surgical’s independent VC arm, which bolstered research, product development, and market expansion efforts.

Attribute	Information
Founding Date	2009
Headquarters	Miami, Florida, USA
Founders	Alon Mozes, Juan Salcedo
Revenue	$17.8 million (2024)
Profits	Not Publicly Disclosed
Key Investors	Mirae Asset Financial Group, NVIDIA
Industry	Medical Robotics
Number of Employees	Approximately 147 as of 2024

Early History

Neocis was founded in 2009 by Alon Mozes and Juan Salcedo, both formerly associated with MAKO Surgical, a pioneer in orthopedic robotics. They envisioned expanding robotic surgery to the dental sector, a market they saw as underserved. By 2012, Neocis developed a fundable prototype, attracting early investment from robotics pioneer Fred Moll. In 2015, Neocis gained FDA clearance for their flagship Yomi system, enabling them to proceed with the commercialization of robotic dental surgery.

Company Profile and Achievements

Neocis developed Yomi, a robotic-assisted surgical system designed to aid in dental implants. Yomi enhances the precision of dental implant procedures by allowing for preoperative planning and real-time haptic guidance. Since its inception, Neocis has consistently expanded upon Yomi’s capabilities, including the significant advancement to full-arch surgical procedures in 2020.

2019: Yomi launched commercially in the USA after initial FDA approval.
2020: Full-arch surgery capabilities added following further FDA clearance.
Funding Milestones: Neocis raised $72 million in Series D funding, underscoring investor confidence in its innovative solutions.

Current Operations and Market Position

Neocis is currently a leading player in the dental robotics market, focusing on enhancing dental implant surgeries with advanced technology. The Yomi system is utilized extensively across North America and is recognized for improving surgical outcomes with precision and reducing recovery times. The company continuously invests in R&D for further innovations and anticipates expanding its market reach internationally.

Conclusion

Neocis stands as an innovator in the field of dental surgery, leveraging advanced robotics to improve procedural efficacy and patient outcomes. With significant funding raised and ongoing expansion initiatives, Neocis is well-positioned to lead the dental robotics space and expand its influence beyond current markets. As the company continues to grow, its commitment to technological advancements portends a promising future in enhancing dental surgical practices worldwide.